The ESMO Clinical Practice Guidelines on bone health in cancer recommend that women with breast cancer receiving aromatase inhibitors and men with prostate cancer receiving ADT should have a fracture risk assessment based on the presence of clinical risk factors and BMD [21]. Here, CYP19A1 is linked to breast cancer.